Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant Familial Mediterranean Fever (FMF)
Authors' conclusion
Treatment with anti-IL-1 agents in children with FMF is effective and safe and may potentiate long-term growth.
Study context
- Population
- Pediatric FMF patients followed in one centre; 22 treated with anakinra (36.3%) and/or canakinumab (90.9%)22 treated with IL-1 blockers
- Participants
- 646 patients
- Exposure
- Height and weight percentiles before vs after anti-IL-1 treatment
- After treatmentn = 22
- Outcome
- Long-term body weight and height trajectories (height and weight percentiles before and after treatment)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Height percentile, before vs after anti-IL-1 treatment
Significant increase in height percentile following treatment
19.6 ± 16% vs. 30.8 ± 23%
Observational data: associations, not effects.
Further findings
- Body weight percentile, before vs after anti-IL-1 treatment — Significant increase in body weight percentile following treatment · 29.5 ± 30% vs. 39.1 ± 36%
- 29.5 ± 30% vs. 39.1 ± 36% · P = 0.043
Original publication
Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF. Pediatr Rheumatol Online J. Published 9 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →